Warning! GuruFocus detected
1 Medium warning sign
with MEGA.
Try a 7-Day Free Trial
to check it out.
What is a stock summary page? Click here for an overview.
Business Description
Mega Lifesciences PCL
ISIN : TH4984010009
Compare
Compare
Traded in other countries / regions
MEGA.Thailand IPO Date
2013-11-19Description
Mega Lifesciences PCL manufactures and sells through independent distributors of health food supplements, branded prescription pharmaceutical products, over-the-counter products, herbal products, vitamins, and fast-moving consumer goods as well as provides distribution services relating to such products. The company's product portfolio consists of health food supplements, branded prescription pharmaceutical products, over-the-counter products, herbal products, vitamins, and fast-moving consumer goods. Its segments include Brands in which goods are manufactured and sold under brands owned by the group; Distribution in which the group provides logistical and marketing services for goods trading purposes and sale of goods manufactured by third parties; and OEM.
Financial Strength
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 7.76 | |||||
| Equity-to-Asset | 0.7 | |||||
| Debt-to-Equity | 0.05 | |||||
| Debt-to-EBITDA | 0.18 | |||||
| Interest Coverage | 87.54 | |||||
| Piotroski F-Score | 8/9 | |||||
| Altman Z-Score | 6.89 | |||||
| Beneish M-Score | -2.44 | |||||
| WACC vs ROIC | ||||||
Growth Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 2.8 | |||||
| 3-Year EBITDA Growth Rate | 1.2 | |||||
| 3-Year EPS without NRI Growth Rate | 16.4 | |||||
| 3-Year FCF Growth Rate | -5.8 | |||||
| 3-Year Book Growth Rate | 7.3 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 2.52 |
Momentum Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 19.4 | |||||
| 9-Day RSI | 30.13 | |||||
| 14-Day RSI | 36.69 | |||||
| 3-1 Month Momentum % | -4.41 | |||||
| 6-1 Month Momentum % | -16.67 | |||||
| 12-1 Month Momentum % | -21.69 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 2.61 | |||||
| Quick Ratio | 1.84 | |||||
| Cash Ratio | 0.97 | |||||
| Days Inventory | 153.5 | |||||
| Days Sales Outstanding | 72.92 | |||||
| Days Payable | 92.88 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 5.25 | |||||
| Dividend Payout Ratio | 0.48 | |||||
| 3-Year Dividend Growth Rate | 14.7 | |||||
| Forward Dividend Yield % | 5.25 | |||||
| 5-Year Yield-on-Cost % | 13.79 | |||||
| Shareholder Yield % | 4.65 |
Profitability Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 50.54 | |||||
| Operating Margin % | 21.96 | |||||
| Net Margin % | 13.12 | |||||
| FCF Margin % | 13.97 | |||||
| ROE % | 20.9 | |||||
| ROA % | 14.14 | |||||
| ROIC % | 40.42 | |||||
| 3-Year ROIIC % | 220.97 | |||||
| ROC (Joel Greenblatt) % | 49.3 | |||||
| ROCE % | 23.8 | |||||
| Years of Profitability over Past 10-Year | 10 |
GF Value Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 13.18 | |||||
| Forward PE Ratio | 11.58 | |||||
| PE Ratio without NRI | 9.22 | |||||
| Shiller PE Ratio | 17.06 | |||||
| Price-to-Owner-Earnings | 12.44 | |||||
| PEG Ratio | 0.82 | |||||
| PS Ratio | 1.73 | |||||
| PB Ratio | 2.7 | |||||
| Price-to-Tangible-Book | 3.11 | |||||
| Price-to-Free-Cash-Flow | 12.38 | |||||
| Price-to-Operating-Cash-Flow | 11.05 | |||||
| EV-to-EBIT | 9.74 | |||||
| EV-to-Forward-EBIT | 8.64 | |||||
| EV-to-EBITDA | 8.71 | |||||
| EV-to-Forward-EBITDA | 7.77 | |||||
| EV-to-Revenue | 1.51 | |||||
| EV-to-Forward-Revenue | 1.49 | |||||
| EV-to-FCF | 11.77 | |||||
| Price-to-GF-Value | 0.74 | |||||
| Price-to-Projected-FCF | 0.94 | |||||
| Price-to-DCF (Earnings Based) | 0.34 | |||||
| Price-to-DCF (FCF Based) | 0.4 | |||||
| Price-to-Median-PS-Value | 0.68 | |||||
| Price-to-Peter-Lynch-Fair-Value | 0.89 | |||||
| Price-to-Graham-Number | 1.13 | |||||
| Price-to-Net-Current-Asset-Value | 4.51 | |||||
| Earnings Yield (Greenblatt) % | 10.29 | |||||
| FCF Yield % | 8.06 | |||||
| Forward Rate of Return (Yacktman) % | 16.87 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Mega Lifesciences PCL Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil ฿) | 15,344.136 | ||
| EPS (TTM) (฿) | 2.313 | ||
| Beta | 0.73 | ||
| 3-Year Sharpe Ratio | -0.54 | ||
| 3-Year Sortino Ratio | -0.71 | ||
| Volatility % | 17.01 | ||
| 14-Day RSI | 36.69 | ||
| 14-Day ATR (฿) | 0.967637 | ||
| 20-Day SMA (฿) | 32.4 | ||
| 12-1 Month Momentum % | -21.69 | ||
| 52-Week Range (฿) | 29.75 - 43.75 | ||
| Shares Outstanding (Mil) | 871.87 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 8 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Mega Lifesciences PCL Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Mega Lifesciences PCL Stock Events
| Event | Date | Price (฿) | ||
|---|---|---|---|---|
| No Event Data | ||||
Mega Lifesciences PCL Frequently Asked Questions
What is Mega Lifesciences PCL(BKK:MEGA)'s stock price today?
The current price of BKK:MEGA is ฿30.50. The 52 week high of BKK:MEGA is ฿43.75 and 52 week low is ฿29.75.
When is next earnings date of Mega Lifesciences PCL(BKK:MEGA)?
The next earnings date of Mega Lifesciences PCL(BKK:MEGA) is .
Does Mega Lifesciences PCL(BKK:MEGA) pay dividends? If so, how much?
The Dividend Yield %  of Mega Lifesciences PCL(BKK:MEGA) is 5.25% (As of Today), Highest Dividend Payout Ratio of Mega Lifesciences PCL(BKK:MEGA) was 0.61. The lowest was 0.4. And the median was 0.51. The  Forward Dividend Yield % of Mega Lifesciences PCL(BKK:MEGA) is 5.25%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers